Skip to content
Open access

In Vivo Transcriptomics-Based Framework for Systematic Indication Expansion

Oct 2026 · bioRxiv · 0 citations · 61 references
Biology

TL;DR

An in vivo transcriptomics-based drug repurposing framework that profiles multi-organ RNA-seq from drug-treated rodents to model systemic drug responses and match tissue-specific drug signatures against a compendium of disease signatures for indication expansion is presented.

Abstract

Capturing the systemic effects of drugs in vivo remains a fundamental challenge for drug repurposing strategies. Here, we present an in vivo transcriptomics-based drug repurposing framework that profiles multi-organ RNA-seq from drug-treated rodents to model systemic drug responses and match tissue-specific drug signatures against a compendium of disease signatures for indication expansion. We applied this framework to semaglutide, a GLP-1 receptor agonist originally developed for diabetes and subsequently expanded for several other indications. By harmonizing more than 900 human disease transcriptomic signatures via agentic AI and using Z-transformed reversal of gene expression scoring to quantify drug-disease relationships, our approach successfully recovered established semaglutide indications while deprioritizing Alzheimer’s disease, an indication for which semaglutide was not effective. Top predictions for common diseases were supported by real-world electronic health record data from the Mount Sinai Health System and several predictions for rare indications are proposed for further investigation. This framework provides a scalable strategy for indication expansion across diverse therapeutic agents, especially investigational compounds for which real-world evidence remains sparse. One Sentence Summary Comparing drug and disease expression profiles from in vivo contexts achieves indication profiles reflective of the interconnected mammalian organism.

Read PDF

Similar papers

Review Open access 2026

AI-Assisted Gene Expression Signature Reversal for Candidate Prioritization in Drug Repurposing

: Drug repurposing increasingly relies on transcriptomic evidence to identify new therapeutic uses for existing drugs or drug-like compounds. This review examines how AI-assisted gene expression signature reversal contributes to candidate prioritization in drug repurposing. The approach compares disease-associated gene...

Yi Wan · 0 citations
Open access Sep 2026

Conjunctive Targeting Links Drug Synergy to Emergent Proteome Structural States

Combinatorial therapies are widely used in the treatment of acute myeloid leukemia (AML) to address disease heterogeneity, adaptive resistance, and rewired signaling and metabolic states. Yet drug prioritization remains largely guided by clinical or phenotypic evidence, while the molecular mechanisms underlying effecti...

Guo-Qing Cheng, R. Soliymani, Elham Gholizadeh et al. · 0 citations
Open access Oct 2026

Integrative drug discovery for Parkinson’s disease with DIMER

Translating Parkinson’s disease (PD) genetics into therapeutic candidates requires approaches that account for interconnected disease mechanisms and their cellular context. Here we present DIMER (Direct and Indirect Module Evaluation for Repurposing and screening), a framework that connects network-based drug repurposi...

Shuai Guo, Xing-Yi Yang, Yi Dong et al. · 0 citations
Open access Oct 2026

drugMR: A multi-omics pipeline for genetically anchored drug-target discovery

DrugMR is a Nextflow pipeline that runs cis-Mendelian randomisation, colocalisation, SMR-HEIDI with bulk and/or single-cell QTLs, three-trait colocalisation and a phenome-wide screen for adverse effects and repurposing, applied to schizophrenia with brain pQTLs.

G. C. Cimadevila, Marie-Joe Dib, M. Bracher-Smith et al. · 0 citations
Review Open access Oct 2026

An AI-Enabled Translational Drug Discovery Framework for NALCN Channelopathy: From High-Throughput Screening to Therapeutic Candidate

Background More than 90% of rare diseases lack an approved therapy, partly reflecting economic barriers in developing treatments for small patient populations. A common bottleneck is costly and resource-intensive hit-to-lead prioritization. Congenital contractures of the limbs and face, hypotonia, and developmental del...

N. Thongsepee, Jeremy A. Tanner, Srikanth R. Polusani et al. · 0 citations
Open access Oct 2026

AI-enabled drug repurposing in Alzheimer’s disease: from computational nomination to pharmacological proof

Rather than cataloguing methods and candidates, this work appraise leading drugs at the individual-molecule level and proposes explicit criteria for progression from computational nomination to clinical testing, which defines seven requirements for clinical progression.

Xin-Zhong Li, Illana Gozes · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.